Clinical trials: SARS-CoV-2
SARS-CoV-2
Efficacy and Safety of Emapalumab and Anakinra in Reducing Hyperinflammation and Respiratory Distress in Patients With COVID-19 Infection.
Hyper-inflammation, caused by a cytokine storm resulting from an exaggerated response of the immune system in the presence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is considered to represent one of the…
- Trial name
- NCT04324021
- Testing
- Emapalumab, Anakinra
- Where
- 12 sites in United States, Italy
- Volunteers
- 16 people
- Sponsor
- Swedish Orphan Biovitrum
COVID-19
A Study of a Potential Oral Treatment to Prevent COVID-19 in Adults Who Are Exposed to Household Member(s) With a Confirmed Symptomatic COVID-19 Infection
The purpose of this clinical trial is to learn whether the study medicine prevent symptoms of COVID-19 in adults who have been exposed to household member(s) with a confirmed symptomatic COVID-19 infection.
- Trial name
- NCT05047601
- Testing
- PF-07321332, Ritonavir
- Where
- 170 sites in United States, Argentina and 15 more
- Volunteers
- 2,954 people
- Sponsor
- Pfizer
SARS-CoV-2, COVID-19
Randomized Comparison of Combination Azithromycin and Hydroxychloroquine vs. Hydroxychloroquine Alone for the Treatment of Confirmed COVID-19
This is a three-arm randomized trial comparing the efficacy of single agent hydroxychloroquine to the combination of hydroxychloroquine and azithromycin, and to a delayed hydroxychloroquine regimen, which will serve as a…
- Trial name
- NCT04336332
- Testing
- Hydroxychloroquine Sulfate + Azithromycin, Hydroxychloroquine Sulfate
- Where
- 5 sites in United States
- Volunteers
- 75 people
- Sponsor
- Rutgers, The State University of New Jersey
COVID-19
Study of Monovalent and Bivalent Recombinant Protein Vaccines Against COVID-19 in Adults 18 Years of Age and Older
The purpose of this Phase III study is to assess the efficacy, safety, and immunogenicity of two CoV2 preS dTM-AS03 vaccines (monovalent and bivalent) as part of primary series vaccinations in a multi-stage approach, as well as a…
- Trial name
- VAT00008 (NCT04904549)
- Testing
- SARS-CoV-2 adjuvanted recombinant protein vaccine (monovalent D614) (primary series), SARS-CoV-2 adjuvanted recombinant protein vaccine (bivalent D614 + B.1.351) (primary series), SARS-CoV-2 adjuvanted recombinant protein vaccine (monovalent B.1.351) (booster dose) >= 4 months after last vaccination
- Where
- 86 sites in United States, Colombia and 9 more
- Volunteers
- 23,670 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
COVID, Sars-CoV2
Defibrotide Therapy for SARS-CoV2 (COVID-19) Acute Respiratory Distress Syndrome (ARDS)
This clinical trial will enroll participants that have pneumonia caused by the COVID-19 virus. During the study patients will receive 7 to up to 14 days of defibrotide.
- Conditions
- COVID, Sars-CoV2, COVID-19, Acute Respiratory Distress Syndrome
- Trial name
- NCT04530604
- Testing
- Defibrotide
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Gregory Yanik
COVID-19, SARS-CoV2
A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Preventing SARS-CoV-2 Infection and COVID-19 in Nursing Home Residents and Staff
The purpose of this study is to evaluate whether LY3819253 given alone and with LY3832479 prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and coronavirus disease - 2019 (COVID-19).
- Trial name
- BLAZE-2 (NCT04497987)
- Testing
- Bamlanivimab, Etesevimab
- Where
- 27 sites in United States
- Volunteers
- 1,180 people
- Sponsor
- Eli Lilly and Company
COVID-19, SARS-CoV-2
Phase II/III Study of AZD2816, for the Prevention of COVID-19 in Adults
The aim of the study is to assess the safety, and immunogenicity of AZD2816 for the prevention of coronavirus disease 2019 (COVID-19).
- Trial name
- AZD2816 (NCT04973449)
- Testing
- AZD1222, AZD2816
- Where
- 35 sites in Brazil, Poland and 2 more
- Volunteers
- 2,843 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Health Behavior, Health Care Utilization
COVID-19: Healthy Oregon (Oregon Saludable): Together We Can (Juntos Podemos) Phase II
The global SARS-CoV-2 pandemic that causes the severe respiratory illness COVID-19 is the worst health crisis that the United States has faced in a century.
- Trial name
- OSJP (NCT05082935)
- Testing
- Phase II Promotores de Salud, Phase I Promotores de Salud Outreach
- Where
- United States
- Volunteers
- 1,463 people
- Sponsor
- University of Oregon
SARS-CoV-2 Infection
A COVID-19 Study to Evaluate Safety and PK of COVID-HIG Administered Through IM, SC, or IV Routes to SARS-CoV-2 Uninfected Adults
The primary objectives of this open-label trial were to evaluate the safety and pharmacokinetics (PK) of Anti-SARS-CoV-2 Immunoglobulin (Human) Investigational Product (COVID-HIG) administered intramuscularly (IM), subcutaneously…
- Trial name
- NCT05142306
- Testing
- COVID-HIG
- Where
- 2 sites in United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Emergent BioSolutions
COVID-19, Vaccine-Preventable Diseases
The Efficacy of the 2023-2024 Updated COVID-19 Vaccines Against COVID-19 Infection
The purpose of this research study is to find out how well two different 2023-2024 updated COVID-19 vaccines protect people from COVID-19 (the disease caused by the SARS-CoV-2 virus), and to determine if getting a 2023-2024…
- Conditions
- COVID-19, Vaccine-Preventable Diseases, SARS CoV 2 Infection, Upper Respiratory Tract Infection
- Trial name
- BEEHIVE (NCT06065176)
- Testing
- Novavax COVID-19 vaccine (2023-2024 formula XBB containing), Pfizer COVID-19 mRNA vaccine (2023-2024 formula XBB containing)
- Where
- United States
- Volunteers
- 1,188 people, healthy volunteers welcome
- Sponsor
- Sarang K. Yoon, DO, MOH
SARS-CoV 2
Efficacy of Tocilizumab on Patients With COVID-19
This is a randomized, double blind, multi-center study to evaluate the effects of tocilizumab compared to placebo on patient outcomes in participants with confirmed SARS-CoV-2 infection and evidence of systemic inflammation.
- Trial name
- NCT04356937
- Testing
- Tocilizumab
- Where
- 3 sites in United States
- Volunteers
- 243 people
- Sponsor
- Massachusetts General Hospital
COVID-19, SARS-CoV-2
Treatment for COVID-19 in High-Risk Adult Outpatients
This is a randomized trial for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in high-risk adults not requiring hospital admission.The overarching goal of this study is to assess the…
- Trial name
- NCT04354428
- Testing
- Ascorbic Acid, Hydroxychloroquine Sulfate, Azithromycin
- Where
- 6 sites in United States
- Volunteers
- 289 people, healthy volunteers welcome
- Sponsor
- University of Washington
SARS-CoV-2 Virus Infection
Dose Finding Study to Evaluate The Safety, Tolerability and Immunogenicity of an Inactiviated, Adjuvanted SARS-CoV-2 Virus Vaccine Candidate Against Covid-19 in Healthy Subjects
A multicenter, 3-arm randomized dose finding study in the UK to evaluate safety, tolerability and immunogenicity of a vaccine candidate against Covid-19.
- Trial name
- NCT04671017
- Testing
- VLA2001
- Where
- 4 sites in United Kingdom
- Volunteers
- 153 people, healthy volunteers welcome
- Sponsor
- Valneva Austria GmbH
SARS-CoV-2 (Covid19)
Safety and Efficacy of Trans Sodium Crocetinate (TSC) in SARS-CoV-2 (COVID-19) Infected Subjects
This study will assess the safety and efficacy of TSC as a treatment for participants who are infected with SARS-CoV-2 (COVID-19).
- Trial name
- NCT04573322
- Testing
- Trans Sodium Crocetinate, Normal saline
- Where
- Romania
- Volunteers
- 25 people
- Sponsor
- Diffusion Pharmaceuticals Inc
Participants With or Without Stable Co-morbidities Associated With Progression to Severe COVID-19
A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults
The study will evaluate the efficacy of Ad26.COV2.S in the prevention of molecularly confirmed moderate to severe/critical coronavirus disease-2019 (COVID-19), as compared to placebo, in SARS-CoV-2 seronegative adults in the…
- Trial name
- ENSEMBLE 2 (NCT04614948)
- Testing
- Ad26.COV2.S
- Where
- 126 sites in United States, Belgium and 8 more
- Volunteers
- 31,835 people, healthy volunteers welcome
- Sponsor
- Janssen Vaccines & Prevention B.V.
Coronavirus, Covid19
A Study to Evaluate the Safety and Immunogenicity of Vaccine CVnCoV in Healthy Adults in Germany for COVID-19
This study aims to evaluate the safety (in all participants) and reactogenicity (in a subset of participants) of CVnCoV administered as a 2-dose schedule to adult participants 18 years of age or older.
- Conditions
- Coronavirus, Covid19, SARS-CoV-2, Severe Acute Respiratory Syndrome
- Trial name
- NCT04674189
- Testing
- CVnCoV Vaccine
- Where
- Germany
- Volunteers
- 2,357 people, healthy volunteers welcome
- Sponsor
- CureVac
COVID-19, SARS-CoV 2
Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19
The purpose of this study was to evaluate the efficacy of hydroxychloroquine (HCQ) and azithromycin (Azithro) to prevent hospitalization or death in symptomatic adult outpatients with COVID-19 caused by SARS-CoV-2 infection.
- Trial name
- NCT04358068
- Testing
- Hydroxychloroquine (HCQ), Azithromycin (Azithro)
- Where
- 11 sites in United States
- Volunteers
- 20 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
COVID-19
Adaptive COVID-19 Treatment Trial 2 (ACTT-2)
ACTT-2 will evaluate the combination of baricitinib and remdesivir compared to remdesivir alone. Subjects will be assessed daily while hospitalized.
- Trial name
- NCT04401579
- Testing
- Remdesivir, Baricitinib
- Where
- 71 sites in United States, Denmark and 6 more
- Volunteers
- 1,033 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
COVID-19, SARS-CoV-2 Infection
Novel Experimental COVID-19 Therapies Affecting Host Response
The overarching goal of the Master Protocol is to find effective strategies for inpatient management of patients with COVID-19. Therapeutic goals for patients hospitalized for COVID-19 include hastening recovery and preventing…
- Conditions
- COVID-19, SARS-CoV-2 Infection, Coronavirus Infection
- Trial name
- NECTAR (NCT04924660)
- Testing
- TXA127, TRV027, Fostamatinib
- Where
- 51 sites in United States
- Volunteers
- 1,060 people
- Sponsor
- Sean Collins
COVID-19, Pneumonia
A Study of LY3127804 in Participants With COVID-19
A randomized, double-blind, placebo-controlled, clinical trial of LY3127804 in participants who are hospitalized with pneumonia and presumed or confirmed COVID-19.
- Trial name
- NCT04342897
- Testing
- LY3127804
- Where
- 13 sites in United States
- Volunteers
- 95 people
- Sponsor
- Eli Lilly and Company